US20100143577A1 - Percutaneous access device system facilitating cell growth thereon - Google Patents
Percutaneous access device system facilitating cell growth thereon Download PDFInfo
- Publication number
- US20100143577A1 US20100143577A1 US12/701,784 US70178410A US2010143577A1 US 20100143577 A1 US20100143577 A1 US 20100143577A1 US 70178410 A US70178410 A US 70178410A US 2010143577 A1 US2010143577 A1 US 2010143577A1
- Authority
- US
- United States
- Prior art keywords
- neck region
- cell growth
- portal
- exterior
- neck
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/022—Artificial gland structures using bioreactors
Definitions
- the present invention in general relates to percutaneous access devices and in particular to a percutaneous access device amenable to skin growth around the device periphery so as to form a biologically stable seal.
- a common problem associated with implantation of a percutaneous access device is skin regeneration about the periphery of the device to form an immunoprotective seal against infection.
- New cell growth and maintenance is typically frustrated by the considerable mechanical forces exerted on the interfacial layer of cells.
- subject cells are often harvested and grown in culture onto PAD surfaces for several days prior to implantation in order to allow an interfacial cell layer to colonize PAD surfaces in advance of implantation.
- cell culturing has met with limited acceptance owing to the need for a cell harvesting surgical procedure preceding the implantation procedure. Additionally, maintaining tissue culture integrity is also a complex and time-consuming task.
- a biocompatible implantable portal has a wall defining a communicative passage through an interior bore.
- the exterior of the portal has a neck region adapted to promote autologous cell growth on the neck region.
- a series of channels are provided on the exterior neck region to facilitate autologous cell growth while disfavoring fluid pooling and bacterial growth. Typical channel widths are from 20 to 300 microns, with adjacent channels being separated by plateaus having a width of between 0 and 600 microns.
- Providing the portal exterior neck region with a texture varying on a nanometer length scale facilitates autologous cell growth. Applying a coating such as a tissue scaffolding matrix to the neck region prior to implantation also facilitates cell growth.
- a coupling or a manifold encompassing the neck region facilitates the draw of vacuum and/or mechanical protection for the growing cells.
- a process for producing a biocompatible implantable portal having a nanoporous surface includes dispersing nanocrystals in a polymer to yield a polymer dispersion.
- the polymer dispersion is applied onto the surface of a portal. Exposing the polymer dispersion on the surface to a solution selectively dissolves the nanocrystals from the surface to create the nanoporous surface.
- An alternative process includes forming a dual domain coating having a first domain type and a second domain type dispersed through the coating on the portal. Selectively removing the first domain type leaves the material of the second domain type in place to yield the porous surface.
- FIG. 1 is a composite perspective view depicting two exemplary cell growth channel pattern halves to an inventive percutaneous access device joined together where the cell growth channels are not depicted to scale for visual clarity;
- FIG. 2 is a plan view of the percutaneous access device depicted in FIG. 1 with a cross-sectional view along with a cross-sectional view of a vacuum manifold coupled thereto;
- FIG. 3 is a perspective view of a cell growth channel according to the present invention.
- the present invention has utility as a protective assembly for a portal for the coupling of a permanent or semi-permanent medical intervention, the portal having an interior bore through which communication is maintained between the portal recipient and external medical equipment.
- a portal for the coupling of a permanent or semi-permanent medical intervention
- the portal having an interior bore through which communication is maintained between the portal recipient and external medical equipment.
- Such portals are routinely used in conjunction with mechanical auxiliary ventricles, chronic ambulatory peritoneal dialysis, prosthetic limb anchorage to an amputation stump, cochlear or other neurological stimulators, drainage tubes, and vascular access lines as exemplary of instances in which such a portal is used.
- Exemplary of such portals are those detailed in U.S. Pat. Nos.
- PEDs percutaneous access devices
- the stabilization of a PAD within the skin to form a germ-free barrier requires subject cells to grow onto the neck surfaces of the PAD adjacent to the subject's epidermis.
- the present invention uses alone, or in combination cell channeling contours, porous biodegradable polymers and the application of vacuum to promote cellular growth towards the surface the neck of a PAD.
- the present invention in facilitating rapid cellular colonization of a PAD neck allows the subject to act as their own cell culture facility and as such affords more rapid stabilization of the PAD, and lower incidence of separation and infection.
- the portal 10 has an opening 12 defined by a sidewall 14 , the exterior side of the wall 14 defining a neck region 16 adapted to promote growth of autologous fibroblast cells thereon.
- a suitable exterior side surface substrate for fibroblast growth is a nanotextured polycarbonate (LEXAN) as detailed as a sleeve in U.S. Pat. No. 4,634,422.
- LEXAN nanotextured polycarbonate
- the process of fission product bombardment followed by etching in a base solution detailed yields a range of pits and pores that vary in size to an extent that some of the pores are large enough to harbor pools of extracellular fluid and bacteria.
- a preferred method of generating a nanotextured neck surface yields pore sizes that are uniformly less than 500 to provide an anchor point for a fibroblast podocyte, while having dimensions that disfavor bacterial colonization. More preferably, a nanotextured surface as used herein has a uniform distribution of 50 to 500 nanometer median dimension indentations. Most preferably, the indentations have a median dimension of between 100 and 300 nanometers.
- a method of forming such pores in a ceramic or metal neck involves impregnating a porous polymer such as a polyurethane with particulate and combusting the polymer under conditions that allow the particles to sinter to form a porous surface with the desired properties.
- a porous polymer such as a polyurethane
- U.S. Pat. No. 4,004,933 details such a process.
- An analogous porous polymeric neck is formed by forming an interpenetrating polymer network in which the two networks are not cross linked. Exposing the resultant structure to a condition such as a solvent digestive towards only one type of interpenetrating polymer network domain yields a porous surface. It is appreciated that the domain need not be uniform in dimension.
- the second domain type remaining after digestion or dissolution of the first domain type is formed as globular, spherical or other shape that is present at or above the percolation threshold such that these second domains are cross linked, sintered or otherwise adhered to yield a porous surface coating.
- Representative second domain types operative herein illustratively include metals, ceramics, and polymeric beads.
- combustion of a polymer containing metal or ceramic ions or inclusions yields a porous coating of the second domain type of the metal, the metal oxide or ceramic.
- Polyacrylic acid and polycarbonate are representative of water soluble and organic solvent polymers, respectively.
- an acid etchable, biocompatible nanocrystal such as silver or silica is dispersed in a polymer melt such as polycarbonate and a neck either formed directly therefrom or the nanocrystal-doped polymer is coated onto a neck substrate.
- voids are formed in the polymer reflective of the original nanocrystal dopant.
- silver is readily dissolved in 6 N hydrochloric acid while silica is dissolved in concentrated hydrofluoric acid. Dissolution in the presence of sonication is appreciated to facilitate the process.
- Nanocrystal loading of 1 to 10 percent by weight, depending on the specific nanocrystal dimensions, is sufficient to achieve the desired uniformity and density of pores.
- channels can take a variety of forms.
- a linear channel 24 and a chrysanthemum-pattern channel 26 are depicted in composite halves as defined by the dashed plane.
- an operative device typically would have a pattern 24 or 26 circumferentially decorating the device surface.
- Other channel patterns operative herein include any pattern that disfavors bacterial pocket formation.
- Specific patterns operative herein are those associated with vehicle tire treads with the proviso that sharp angular interactions between channel and intermediate plateaus are disfavored. Representative of these patterns are those found in U.S. Pat. No. 5,896,905.
- the channel 22 is formed by methods such as imprinting, embossing, molding or machining into the portal 10 .
- the portal 10 is a nanotextured surface as detailed in regard to the sleeve in U.S. Pat. No. 4,634,422.
- a portal 10 is formed of a conventional biocompatible material, one of skill in the art will appreciate the relative merits of impressing, embossing, machining, or molding based on whether the portal 10 is formed of a metal such as stainless steel, or titanium; a thermoplastic such as a fluoropolymer (TEFLON), a polyoxymethylene (DELRIN), or polycarbonate (LEXAN); or composite material.
- TEFLON fluoropolymer
- DELRIN polyoxymethylene
- LEXAN polycarbonate
- a channel 22 according to the present invention preferably has dimensions on the order of two to ten times the diameter of a plasma-borne fibroblast that is equivalent to 20 to 300 microns since a fibroblast has a diameter from 10 to 15 microns. More preferably, an inventive channel 22 has a width of between 30 and 120 microns. Most preferably, channel 22 is devoid of discontinuities and acute angles that disfavor cellular planarization and adhesion. A parabolic cross section is exemplary of a channel facilitating fibroblast growth. Typically, the plateau region between adjacent channels 22 has a width ranging from 0 to 600 microns.
- the transition between the channel 22 and the plateau 30 is devoid of discontinuities and acute angles that disfavor cellular planarization and adhesion.
- a non-existent zero micron width plateau 30 corresponds to the instance where the cross section between channels corresponds to a sinusoidal pattern or the edges of adjacent parabolic channels intersect.
- a plateau 30 has a width relative to an adjacent channel width that defines a ratio between 0.5 and 3:1. The alternation of channels 22 and plateaus 30 according to the present invention facilitates capillary draw of fibroblasts up into the neck region 16 of the inventive device 10 .
- the neck region 16 is coated with a substance to facilitate cellular infiltration and growth on the neck region 16 .
- coating substances include cell growth scaffolding matrices as detailed in U.S. Pat. Nos. 5,874,500; 6,056,970; and 6,656,496; and Norman et al. Tissue Eng. 3/2005, 11(3-4) pp. 375-386.
- autologous plasma from the subject receiving an inventive portal 10 is applied to the neck region 16 as part of a scaffold matrix or independent thereof.
- the coating 32 is porous in order to enhance capillary draw. More preferably, the coating 32 is porous and biodegradable.
- the coating has pores typically of an average size of between 10 and 500 microns, and preferably, of an average size of between 30 and 50 microns.
- a vacuum is drawn toward an upward region of the neck region 16 in order to actively draw blood plasma and fibroblasts contained therein along the channels 22 to further facilitate autologous cell growth on the neck region 16 .
- vacuum is applied intermittently for the first days or weeks after PAD implantation. The length of time for which vacuum is applied is dependent upon variables illustratively including vacuum strength, linear dimension of the neck region to be colonized, channel pattern, porosity characteristics of any coating present, subject wound fluid production, and subject serum fibroblast concentration.
- a vacuum manifold 40 is secured to an inventive portal 10 by way of a fastener 42 .
- the fastener 42 extends into a temporary seating pin (not shown) to fit within the opening 12 .
- a spacer 44 assures a uniform gap between the manifold 40 and the neck region 16 .
- An inlet 46 is provided for the coupling of the manifold 40 to a vacuum source.
- Manifold 40 has an extending lip 48 that terminates proximal to a surface of the neck portion 16 at least one point amenable to form a seal 50 with the surrounding subject skin or a gel applied to the user skin.
- a retaining groove 54 is defined on a lip surface in opposition to the portal neck portion 16 , the retaining groove 54 amenable to seat a vacuum gasket between the manifold 40 and the neck portion 16 .
- a gasket used herein is formed of conventional materials illustratively including neoprene. While the skin seal 50 is suitable to draw a vacuum around the periphery of the neck portion 16 , cells that are drawn within the portal portion under vacuum tend to be drawn to a surface of the neck portion 16 as opposed to intercalating within a channel or a matrix coating.
- drawing of cells to the uppermost reaches of channels 22 preferably occurs by forming a vacuum seal between the manifold 40 and the neck portion 16 that includes only the uppermost terminus of the channels 22 . It is appreciated that once cells 31 begin to adhere to a surface defining a portion of a channel 22 or plateau 30 , abrasion and indeed contact with that surface is preferably avoided. It is further appreciated that a retaining groove 54 and the ensuing vacuum seal formed between the manifold 40 and the neck portion 16 is readily moved relative to the neck portion 16 by varying the thickness of the spacer 44 .
- an inlet 46 can be connected to a gas supply such as air or oxygen to promote autologous cell growth and granulation about the neck portion 16 ; or liquid solutions fostering cell growth are also provided and illustratively include autologous plasma, fibroblast growth enhancing solutions, and antimicrobials.
- a vacuum source suitable for coupling to the inlet 46 includes conventional vacuum sources such as a mechanical pump, aspirator, peristaltic pump, and the pneumatic system of a left ventricular assist device of a system such as the Kantrowitz CARDIOVAD drive unit as detailed at Ivadtech.com.
- a fibroblast compatible dye (not shown) is placed in proximity to channel termini nearest the implanted region 18 , the dye serving as a marker to indicate the extent of capillary draw of cells 31 into channels 22 and the optionally present coating 32 .
- Patent documents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These documents and publications are incorporated herein by reference to the same extent as if each individual document or publication was specifically and individually incorporated herein by reference.
Landscapes
- Health & Medical Sciences (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
A biocompatible implantable portal is provided that has a wall defining a communicative passage through an interior bore. The exterior of the portal has a neck region adapted to promote autologous cell growth on the neck region. A series of channels are provided on the exterior neck region to facilitate autologous cell growth while disfavoring fluid pooling and bacterial growth. Typical channel widths are from 20 to 300 microns, with adjacent channels being separated by plateaus having a width of between 0 and 600 microns. Providing the portal exterior neck region with a texture varying on a nanometer length scale facilitates autologous cell growth. Applying a coating such as a tissue scaffolding matrix to the neck region prior to implantation also facilitates cell growth. A coupling or a manifold encompassing the neck region facilitates the draw of vacuum and/or mechanical protection for the growing cells.
Description
- This application is a divisional application of U.S. patent application Ser. No. 11/460,339 filed Jul. 27, 2006, which claims priority of U.S. Provisional Patent Application 60/703,661 filed Jul. 29, 2005, these applications are incorporated herein by reference.
- The present invention in general relates to percutaneous access devices and in particular to a percutaneous access device amenable to skin growth around the device periphery so as to form a biologically stable seal.
- A common problem associated with implantation of a percutaneous access device (PAD) is skin regeneration about the periphery of the device to form an immunoprotective seal against infection. New cell growth and maintenance is typically frustrated by the considerable mechanical forces exerted on the interfacial layer of cells. In order to facilitate skin regeneration about the exterior of a PAD, subject cells are often harvested and grown in culture onto PAD surfaces for several days prior to implantation in order to allow an interfacial cell layer to colonize PAD surfaces in advance of implantation. Unfortunately, cell culturing has met with limited acceptance owing to the need for a cell harvesting surgical procedure preceding the implantation procedure. Additionally, maintaining tissue culture integrity is also a complex and time-consuming task.
- As an alternative to cell culturing on a percutaneous access device, vacuum assisted wound treatment about a percutaneous access device has been attempted. While Dacron based random felt meshes have been used to promote cell regrowth in the vicinity of a wound, such felts have uncontrolled pore sizes that harbor bacterial growth pockets.
- Thus, there exists a need for a percutaneous access device surface and processes to enhance autologous cell growth into a stable long term relation to the device.
- A biocompatible implantable portal is provided that has a wall defining a communicative passage through an interior bore. The exterior of the portal has a neck region adapted to promote autologous cell growth on the neck region. A series of channels are provided on the exterior neck region to facilitate autologous cell growth while disfavoring fluid pooling and bacterial growth. Typical channel widths are from 20 to 300 microns, with adjacent channels being separated by plateaus having a width of between 0 and 600 microns. Providing the portal exterior neck region with a texture varying on a nanometer length scale facilitates autologous cell growth. Applying a coating such as a tissue scaffolding matrix to the neck region prior to implantation also facilitates cell growth. A coupling or a manifold encompassing the neck region facilitates the draw of vacuum and/or mechanical protection for the growing cells.
- By forming a seal between a manifold encompassing the neck region of a portal to form a seal and providing a route of fluid communication between the manifold inlet and channels associated with the portal exterior, various gaseous or liquid fluids are provided to enhance cell growth after implantation of a percutaneous access device is facilitated.
- A process is provided for producing a biocompatible implantable portal having a nanoporous surface. The process includes dispersing nanocrystals in a polymer to yield a polymer dispersion. The polymer dispersion is applied onto the surface of a portal. Exposing the polymer dispersion on the surface to a solution selectively dissolves the nanocrystals from the surface to create the nanoporous surface. An alternative process includes forming a dual domain coating having a first domain type and a second domain type dispersed through the coating on the portal. Selectively removing the first domain type leaves the material of the second domain type in place to yield the porous surface.
-
FIG. 1 is a composite perspective view depicting two exemplary cell growth channel pattern halves to an inventive percutaneous access device joined together where the cell growth channels are not depicted to scale for visual clarity; -
FIG. 2 is a plan view of the percutaneous access device depicted inFIG. 1 with a cross-sectional view along with a cross-sectional view of a vacuum manifold coupled thereto; and -
FIG. 3 is a perspective view of a cell growth channel according to the present invention. - The present invention has utility as a protective assembly for a portal for the coupling of a permanent or semi-permanent medical intervention, the portal having an interior bore through which communication is maintained between the portal recipient and external medical equipment. As a result, the conveyance of electrical signals, pneumatic drive power, or biological fluids is facilitated. Such portals are routinely used in conjunction with mechanical auxiliary ventricles, chronic ambulatory peritoneal dialysis, prosthetic limb anchorage to an amputation stump, cochlear or other neurological stimulators, drainage tubes, and vascular access lines as exemplary of instances in which such a portal is used. Exemplary of such portals are those detailed in U.S. Pat. Nos. 4,634,422; 4,668,222; 5,059,186; 5,120,313; 5,250,025; 5,814,058; 5,997,524; and 6,503,228. Such devices are collectively defined herein as percutaneous access devices (PADs).
- The stabilization of a PAD within the skin to form a germ-free barrier requires subject cells to grow onto the neck surfaces of the PAD adjacent to the subject's epidermis. The present invention uses alone, or in combination cell channeling contours, porous biodegradable polymers and the application of vacuum to promote cellular growth towards the surface the neck of a PAD. The present invention in facilitating rapid cellular colonization of a PAD neck allows the subject to act as their own cell culture facility and as such affords more rapid stabilization of the PAD, and lower incidence of separation and infection.
- Referring now to the figures, an inventive portal is shown generally at 10. The
portal 10 has anopening 12 defined by asidewall 14, the exterior side of thewall 14 defining aneck region 16 adapted to promote growth of autologous fibroblast cells thereon. A suitable exterior side surface substrate for fibroblast growth is a nanotextured polycarbonate (LEXAN) as detailed as a sleeve in U.S. Pat. No. 4,634,422. Unfortunately, the process of fission product bombardment followed by etching in a base solution detailed yields a range of pits and pores that vary in size to an extent that some of the pores are large enough to harbor pools of extracellular fluid and bacteria. A preferred method of generating a nanotextured neck surface yields pore sizes that are uniformly less than 500 to provide an anchor point for a fibroblast podocyte, while having dimensions that disfavor bacterial colonization. More preferably, a nanotextured surface as used herein has a uniform distribution of 50 to 500 nanometer median dimension indentations. Most preferably, the indentations have a median dimension of between 100 and 300 nanometers. - A method of forming such pores in a ceramic or metal neck involves impregnating a porous polymer such as a polyurethane with particulate and combusting the polymer under conditions that allow the particles to sinter to form a porous surface with the desired properties. U.S. Pat. No. 4,004,933 details such a process. An analogous porous polymeric neck is formed by forming an interpenetrating polymer network in which the two networks are not cross linked. Exposing the resultant structure to a condition such as a solvent digestive towards only one type of interpenetrating polymer network domain yields a porous surface. It is appreciated that the domain need not be uniform in dimension. By way of example, the second domain type remaining after digestion or dissolution of the first domain type is formed as globular, spherical or other shape that is present at or above the percolation threshold such that these second domains are cross linked, sintered or otherwise adhered to yield a porous surface coating. Representative second domain types operative herein illustratively include metals, ceramics, and polymeric beads.
- Alternatively, combustion of a polymer containing metal or ceramic ions or inclusions yields a porous coating of the second domain type of the metal, the metal oxide or ceramic. Polyacrylic acid and polycarbonate are representative of water soluble and organic solvent polymers, respectively.
- Alternatively, an acid etchable, biocompatible nanocrystal such as silver or silica is dispersed in a polymer melt such as polycarbonate and a neck either formed directly therefrom or the nanocrystal-doped polymer is coated onto a neck substrate. Through subjecting the nanocrystal-doped polymer to an acid or base solution, depending on the solubility of the nanocrystal, voids are formed in the polymer reflective of the original nanocrystal dopant. For instance, silver is readily dissolved in 6 N hydrochloric acid while silica is dissolved in concentrated hydrofluoric acid. Dissolution in the presence of sonication is appreciated to facilitate the process. Silver represents a preferred nanocrystal as nanocrystal leachant not dissolved imparts antimicrobial properties to the resulting neck. Nanocrystal loading of 1 to 10 percent by weight, depending on the specific nanocrystal dimensions, is sufficient to achieve the desired uniformity and density of pores.
- Beneath the
neck region 16 lies an implantedregion 18 terminating in an inwardportal face 20, that is communicative with theopening 12 to form a passage through which fluids, electrical signals, gases or a combination thereof are communicated. Theneck region 16 has a pattern of contoured autologous cell-conveyingchannels - It is appreciated that the channels can take a variety of forms. In the figures, a
linear channel 24 and a chrysanthemum-pattern channel 26 are depicted in composite halves as defined by the dashed plane. It is appreciated that an operative device typically would have apattern channel 22 is formed by methods such as imprinting, embossing, molding or machining into the portal 10. Preferably, the portal 10 is a nanotextured surface as detailed in regard to the sleeve in U.S. Pat. No. 4,634,422. As a portal 10 is formed of a conventional biocompatible material, one of skill in the art will appreciate the relative merits of impressing, embossing, machining, or molding based on whether the portal 10 is formed of a metal such as stainless steel, or titanium; a thermoplastic such as a fluoropolymer (TEFLON), a polyoxymethylene (DELRIN), or polycarbonate (LEXAN); or composite material. Achannel 22 according to the present invention preferably has dimensions on the order of two to ten times the diameter of a plasma-borne fibroblast that is equivalent to 20 to 300 microns since a fibroblast has a diameter from 10 to 15 microns. More preferably, aninventive channel 22 has a width of between 30 and 120 microns. Most preferably,channel 22 is devoid of discontinuities and acute angles that disfavor cellular planarization and adhesion. A parabolic cross section is exemplary of a channel facilitating fibroblast growth. Typically, the plateau region betweenadjacent channels 22 has a width ranging from 0 to 600 microns. Preferably, the transition between thechannel 22 and theplateau 30 is devoid of discontinuities and acute angles that disfavor cellular planarization and adhesion. A non-existent zeromicron width plateau 30 corresponds to the instance where the cross section between channels corresponds to a sinusoidal pattern or the edges of adjacent parabolic channels intersect. Preferably, aplateau 30 has a width relative to an adjacent channel width that defines a ratio between 0.5 and 3:1. The alternation ofchannels 22 and plateaus 30 according to the present invention facilitates capillary draw of fibroblasts up into theneck region 16 of theinventive device 10. - Optionally, the
neck region 16 is coated with a substance to facilitate cellular infiltration and growth on theneck region 16. Such coating substances include cell growth scaffolding matrices as detailed in U.S. Pat. Nos. 5,874,500; 6,056,970; and 6,656,496; and Norman et al. Tissue Eng. 3/2005, 11(3-4) pp. 375-386. Preferably, autologous plasma from the subject receiving aninventive portal 10 is applied to theneck region 16 as part of a scaffold matrix or independent thereof. More preferably, thecoating 32 is porous in order to enhance capillary draw. More preferably, thecoating 32 is porous and biodegradable. The coating has pores typically of an average size of between 10 and 500 microns, and preferably, of an average size of between 30 and 50 microns. - Optionally, a vacuum is drawn toward an upward region of the
neck region 16 in order to actively draw blood plasma and fibroblasts contained therein along thechannels 22 to further facilitate autologous cell growth on theneck region 16. Preferably, vacuum is applied intermittently for the first days or weeks after PAD implantation. The length of time for which vacuum is applied is dependent upon variables illustratively including vacuum strength, linear dimension of the neck region to be colonized, channel pattern, porosity characteristics of any coating present, subject wound fluid production, and subject serum fibroblast concentration. - Referring now to
FIG. 2 , avacuum manifold 40 is secured to aninventive portal 10 by way of afastener 42. Thefastener 42 extends into a temporary seating pin (not shown) to fit within theopening 12. Aspacer 44 assures a uniform gap between the manifold 40 and theneck region 16. Aninlet 46 is provided for the coupling of the manifold 40 to a vacuum source.Manifold 40 has an extendinglip 48 that terminates proximal to a surface of theneck portion 16 at least one point amenable to form aseal 50 with the surrounding subject skin or a gel applied to the user skin. It is appreciated that a retaininggroove 54 is defined on a lip surface in opposition to theportal neck portion 16, the retaininggroove 54 amenable to seat a vacuum gasket between the manifold 40 and theneck portion 16. A gasket used herein is formed of conventional materials illustratively including neoprene. While theskin seal 50 is suitable to draw a vacuum around the periphery of theneck portion 16, cells that are drawn within the portal portion under vacuum tend to be drawn to a surface of theneck portion 16 as opposed to intercalating within a channel or a matrix coating. As such, it is appreciated that while drawing a vacuum at the interface between theneck portion 16 andlip terminus 52 is suit able to urge an initial population of cells into thechannels 22, drawing of cells to the uppermost reaches ofchannels 22 preferably occurs by forming a vacuum seal between the manifold 40 and theneck portion 16 that includes only the uppermost terminus of thechannels 22. It is appreciated that oncecells 31 begin to adhere to a surface defining a portion of achannel 22 orplateau 30, abrasion and indeed contact with that surface is preferably avoided. It is further appreciated that a retaininggroove 54 and the ensuing vacuum seal formed between the manifold 40 and theneck portion 16 is readily moved relative to theneck portion 16 by varying the thickness of thespacer 44. While the manifold 40 is beneficial in drawing serum and the fibroblasts contained therein through thechannels 22 in theneck portion 16, it is also appreciated that independent of vacuum, the manifold 40 also serves to provide a mechanical guard to protect growing cells on theneck portion 16. To this end, it is appreciated that aninlet 46 can be connected to a gas supply such as air or oxygen to promote autologous cell growth and granulation about theneck portion 16; or liquid solutions fostering cell growth are also provided and illustratively include autologous plasma, fibroblast growth enhancing solutions, and antimicrobials. - A vacuum source suitable for coupling to the
inlet 46 includes conventional vacuum sources such as a mechanical pump, aspirator, peristaltic pump, and the pneumatic system of a left ventricular assist device of a system such as the Kantrowitz CARDIOVAD drive unit as detailed at Ivadtech.com. Optionally, a fibroblast compatible dye (not shown) is placed in proximity to channel termini nearest the implantedregion 18, the dye serving as a marker to indicate the extent of capillary draw ofcells 31 intochannels 22 and the optionallypresent coating 32. - Patent documents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These documents and publications are incorporated herein by reference to the same extent as if each individual document or publication was specifically and individually incorporated herein by reference.
- The foregoing description is illustrative of particular embodiments of the invention, but is not meant to be a limitation upon the practice thereof. The following claims, including all equivalents thereof, are intended to define the scope of the invention.
Claims (3)
1. A process for producing a biocompatible implantable portal having a nanoporous surface comprising:
dispersing a plurality of nanocrystals in a polymer to yield a polymer dispersion;
applying said polymer dispersion onto the portal having a surface; and
exposing said polymer dispersion on the surface to a solution for selectively dissolving said plurality of nanocrystals from the surface to create the nanoporous surface.
2. The process of claim 1 further comprising sonicating said polymer while exposing said polymer to said solution.
3. The process of claim 1 wherein said plurality of nanocrystals are silver nanocrystals.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/701,784 US20100143577A1 (en) | 2005-07-29 | 2010-02-08 | Percutaneous access device system facilitating cell growth thereon |
US13/756,276 US8877499B2 (en) | 2005-07-29 | 2013-01-31 | Bone anchor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70366105P | 2005-07-29 | 2005-07-29 | |
US11/460,339 US7704225B2 (en) | 2005-07-29 | 2006-07-27 | Percutaneous access device system facilitating cell growth thereon |
US12/701,784 US20100143577A1 (en) | 2005-07-29 | 2010-02-08 | Percutaneous access device system facilitating cell growth thereon |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/460,339 Division US7704225B2 (en) | 2003-06-11 | 2006-07-27 | Percutaneous access device system facilitating cell growth thereon |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/372,025 Continuation US8383407B2 (en) | 2005-07-29 | 2012-02-13 | Percutaneous access device system facilitating cell growth thereon |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100143577A1 true US20100143577A1 (en) | 2010-06-10 |
Family
ID=37694585
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/460,339 Active 2028-08-23 US7704225B2 (en) | 2003-06-11 | 2006-07-27 | Percutaneous access device system facilitating cell growth thereon |
US12/701,784 Abandoned US20100143577A1 (en) | 2005-07-29 | 2010-02-08 | Percutaneous access device system facilitating cell growth thereon |
US13/372,025 Active US8383407B2 (en) | 2005-07-29 | 2012-02-13 | Percutaneous access device system facilitating cell growth thereon |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/460,339 Active 2028-08-23 US7704225B2 (en) | 2003-06-11 | 2006-07-27 | Percutaneous access device system facilitating cell growth thereon |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/372,025 Active US8383407B2 (en) | 2005-07-29 | 2012-02-13 | Percutaneous access device system facilitating cell growth thereon |
Country Status (1)
Country | Link |
---|---|
US (3) | US7704225B2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7704225B2 (en) * | 2005-07-29 | 2010-04-27 | L-Vad Technology, Inc. | Percutaneous access device system facilitating cell growth thereon |
US7976452B2 (en) * | 2003-06-11 | 2011-07-12 | L.Vad Technology, Inc. | Long term ambulatory intro-aortic balloon pump with percutaneous access device |
US10065030B2 (en) | 2010-02-23 | 2018-09-04 | Viaderm Llc | Vacuum assisted percutaneous appliance |
ES2659372T3 (en) | 2013-01-23 | 2018-03-15 | C.R. Bard Inc. | Low Profile Access Port |
US11420033B2 (en) | 2013-01-23 | 2022-08-23 | C. R. Bard, Inc. | Low-profile single and dual vascular access device |
US11464960B2 (en) | 2013-01-23 | 2022-10-11 | C. R. Bard, Inc. | Low-profile single and dual vascular access device |
US8915970B2 (en) | 2013-02-08 | 2014-12-23 | Biomet Manufacturing, Llc | Transdermal prosthesis |
JP5751726B2 (en) * | 2013-11-12 | 2015-07-22 | 東京エレクトロン株式会社 | Pluripotent stem cell culture method and facility |
US10791984B2 (en) * | 2014-03-12 | 2020-10-06 | Viaderm, Llc. | Active hermeticity monitoring |
WO2015179862A1 (en) | 2014-05-23 | 2015-11-26 | Viaderm, Llc | Vacuum assisted percutaneous appliance |
US10687956B2 (en) | 2014-06-17 | 2020-06-23 | Titan Spine, Inc. | Corpectomy implants with roughened bioactive lateral surfaces |
US10086184B2 (en) | 2014-10-08 | 2018-10-02 | Alfred E. Mann Foundation For Scientific Research | Method of manufacturing percutaneous ports with wire coils |
US10226612B2 (en) * | 2014-10-08 | 2019-03-12 | Alfred E. Mann Foundation For Scientific Research | Percutaneous ports with wire coils |
EP3265161A4 (en) | 2015-03-04 | 2018-12-19 | Viaderm, LLC | Vacuum assisted skin penetrating appliance with external interface |
US20200254232A1 (en) | 2017-08-16 | 2020-08-13 | Cardiac Assist Holdings | Percutaneous appliance with transdermal collapsible flanges |
USD870264S1 (en) | 2017-09-06 | 2019-12-17 | C. R. Bard, Inc. | Implantable apheresis port |
WO2020102498A1 (en) * | 2018-11-14 | 2020-05-22 | Cardiac Assist Holdings Llc | Chain mail surgical collar and method of percutaneous device stabilization therewith |
EP3917588A2 (en) | 2019-02-01 | 2021-12-08 | Kardiatec SA | Pressure unloading left ventricular assist device and methods for assisting a human heart |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3663965A (en) * | 1970-06-08 | 1972-05-23 | Henry L Lee Jr | Bacteria-resistant percutaneous conduit device |
US3906549A (en) * | 1973-12-18 | 1975-09-23 | Louis Bucalo | Implanting structure and method |
US3964470A (en) * | 1974-07-25 | 1976-06-22 | Medtronic, Inc. | Percutaneous intradermal electrical connection system and implant device |
US3995644A (en) * | 1975-09-16 | 1976-12-07 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Percutaneous connector device |
US4183357A (en) * | 1976-08-02 | 1980-01-15 | Bentley Laboratories, Inc. | Chronic transcutaneous implant assembly for enterostomies |
US4266999A (en) * | 1979-07-30 | 1981-05-12 | Calspan Corporation | Catheter for long-term emplacement |
US4321914A (en) * | 1980-04-22 | 1982-03-30 | W. L. Gore & Associates, Inc. | Percutaneous conduit having PTFE skirt |
US4634422A (en) * | 1984-05-31 | 1987-01-06 | Adrian Kantrowitz | Percutaneous access device and method for implanting same |
US4668222A (en) * | 1984-05-25 | 1987-05-26 | Thermedics Inc. | Percutaneous access device with removable tube |
US4897081A (en) * | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US5242415A (en) * | 1992-08-14 | 1993-09-07 | L-Vad Technology, Inc. | Percutaneous access device |
US6031148A (en) * | 1990-12-06 | 2000-02-29 | W. L. Gore & Associates, Inc. | Implantable bioabsorbable article |
US6039714A (en) * | 1998-05-12 | 2000-03-21 | Novartis Nutrition Ag | Collapsible retention bolster for gastrostomy and other ostomy tubes |
US20030224032A1 (en) * | 2000-04-10 | 2003-12-04 | Read Roger W | Antimicrobial coatings |
US20040170663A1 (en) * | 2002-10-09 | 2004-09-02 | Jennifer H. Elisseeff | Method and material for enhanced tissue-biomaterial integration |
US20050080338A1 (en) * | 1998-12-24 | 2005-04-14 | Sirimanne D. Laksen | Biopsy cavity marking device and method |
US20050181011A1 (en) * | 2003-11-10 | 2005-08-18 | Angiotech International Ag | Medical implants and anti-scarring agents |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4676802A (en) * | 1986-01-21 | 1987-06-30 | J. Tofield, Et Al. | Method and apparatus for securing a prosthesis to the human body |
US7704225B2 (en) * | 2005-07-29 | 2010-04-27 | L-Vad Technology, Inc. | Percutaneous access device system facilitating cell growth thereon |
-
2006
- 2006-07-27 US US11/460,339 patent/US7704225B2/en active Active
-
2010
- 2010-02-08 US US12/701,784 patent/US20100143577A1/en not_active Abandoned
-
2012
- 2012-02-13 US US13/372,025 patent/US8383407B2/en active Active
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3663965A (en) * | 1970-06-08 | 1972-05-23 | Henry L Lee Jr | Bacteria-resistant percutaneous conduit device |
US3906549A (en) * | 1973-12-18 | 1975-09-23 | Louis Bucalo | Implanting structure and method |
US3964470A (en) * | 1974-07-25 | 1976-06-22 | Medtronic, Inc. | Percutaneous intradermal electrical connection system and implant device |
US3995644A (en) * | 1975-09-16 | 1976-12-07 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Percutaneous connector device |
US4183357A (en) * | 1976-08-02 | 1980-01-15 | Bentley Laboratories, Inc. | Chronic transcutaneous implant assembly for enterostomies |
US4266999A (en) * | 1979-07-30 | 1981-05-12 | Calspan Corporation | Catheter for long-term emplacement |
US4321914A (en) * | 1980-04-22 | 1982-03-30 | W. L. Gore & Associates, Inc. | Percutaneous conduit having PTFE skirt |
US4668222A (en) * | 1984-05-25 | 1987-05-26 | Thermedics Inc. | Percutaneous access device with removable tube |
US4897081A (en) * | 1984-05-25 | 1990-01-30 | Thermedics Inc. | Percutaneous access device |
US4634422A (en) * | 1984-05-31 | 1987-01-06 | Adrian Kantrowitz | Percutaneous access device and method for implanting same |
US6031148A (en) * | 1990-12-06 | 2000-02-29 | W. L. Gore & Associates, Inc. | Implantable bioabsorbable article |
US5242415A (en) * | 1992-08-14 | 1993-09-07 | L-Vad Technology, Inc. | Percutaneous access device |
US6039714A (en) * | 1998-05-12 | 2000-03-21 | Novartis Nutrition Ag | Collapsible retention bolster for gastrostomy and other ostomy tubes |
US20050080338A1 (en) * | 1998-12-24 | 2005-04-14 | Sirimanne D. Laksen | Biopsy cavity marking device and method |
US20030224032A1 (en) * | 2000-04-10 | 2003-12-04 | Read Roger W | Antimicrobial coatings |
US20040170663A1 (en) * | 2002-10-09 | 2004-09-02 | Jennifer H. Elisseeff | Method and material for enhanced tissue-biomaterial integration |
US20050181011A1 (en) * | 2003-11-10 | 2005-08-18 | Angiotech International Ag | Medical implants and anti-scarring agents |
Also Published As
Publication number | Publication date |
---|---|
US7704225B2 (en) | 2010-04-27 |
US20120150149A1 (en) | 2012-06-14 |
US8383407B2 (en) | 2013-02-26 |
US20070026032A1 (en) | 2007-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8383407B2 (en) | Percutaneous access device system facilitating cell growth thereon | |
AU645155B2 (en) | Close vascularization implant material | |
US20190167965A1 (en) | Vacuum assisted percutaneous appliance | |
EP1577083A1 (en) | Biodegradable substrate, prosthetic material for tissue regeneration and cultured tissue | |
TW200845948A (en) | Biocompatible wound dressing | |
EP3046519B1 (en) | Method for the production of structured cellulose patches or elements and devices made using such a method | |
JPH10503965A (en) | Implantable containment device for a therapeutic device and method for loading and reloading the device therein | |
US20180043069A1 (en) | Vacuum assisted skin penetrating appliance with external interface | |
US20210161720A1 (en) | Medical dressing removable adhesive strips | |
US12097314B2 (en) | Vacuum assisted skin penetrating appliance with external interface | |
US20220395671A1 (en) | Vacuum dressing for use with guide tube | |
US20220273230A1 (en) | Vacuum dressing with atmospheric control feedback | |
US20200254232A1 (en) | Percutaneous appliance with transdermal collapsible flanges |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |